<DOC>
	<DOCNO>NCT00003554</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance . PURPOSE : Phase II trial study effectiveness monoclonal antibody rituximab treat patient multiple myeloma newly diagnose .</brief_summary>
	<brief_title>Rituximab Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate role rituximab induce apoptosis malignant plasma cell patient multiple myeloma . II . Evaluate role regimen improve response rate melphalan prednisone patient . III . Determine whether regimen decrease residual disease patient . IV . Evaluate toxic effect regimen patient . OUTLINE : Patients receive rituximab IV every week 4 week . Treatment repeat every 6 month six course . Treatment may discontinue four course uncontrolled infection occurs . Patients also receive oral melphalan prednisone 4 day begin first course rituximab . Treatment repeat every 4-6 week least nine course . PROJECTED ACCRUAL : Approximately 40 patient accrue study within 12-24 month .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven , newly diagnose multiple myeloma Eligible pancytopenia relate multiple myeloma At least 50 % plasma cell bone marrow OR Splenomegaly OR Plasma cell leukemia No solitary extramedullary plasmacytoma plasma cell dyscrasia PATIENT CHARACTERISTICS : Age : Not specify Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : If less 50 % plasma cell bone marrow : WBC least 2,500/mm3 OR Absolute neutrophil count least 1,000/mm3 ( great 500/mm3 platelet count least 75,000/mm3 ) Platelet count great 45,000/mm3 ( thrombocytopenia relate idiopathic thrombocytopenic purpura vitamin B12 folate deficiency allow ) Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) ALT AST less 2 time ULN ( great one third liver involve , great 5 time ULN ) No severe hepatic disease Renal : Creatinine great 2.0 mg/dL Other : No severe infection require intravenous antibiotic Not pregnant nursing Fertile patient must use effective contraception No prior malignancy within 5 year except treat basal cell squamous cell skin cancer , carcinoma situ cervix No Type I hypersensitivity anaphylactic reaction murine protein component rituximab PRIOR CONCURRENT THERAPY : Biologic therapy : No prior bone marrow transplantation Concurrent sargramostim ( GMCSF ) allow severe , symptomatic neutropenia Chemotherapy : At least 4 week since investigational drug Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No concurrent use investigational drug device Concurrent epoetin alfa allow anemia Plasmapheresis allow study onset treat renal failure</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>